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Introduction {#bjs577-sec-0005}
============

Primary hyperparathyroidism (PHPT) is a common condition, with an estimated incidence of one to seven per 1000 adults[1](#bjs577-bib-0001){ref-type="ref"}. The condition is detected incidentally in more than 80 per cent of subjects on routine biochemical analysis[2](#bjs577-bib-0002){ref-type="ref"} [3](#bjs577-bib-0003){ref-type="ref"}. Surgery remains the only curative option.

Parathyroid surgery via an open bilateral four‐gland neck exploration was first performed in 1925[4](#bjs577-bib-0004){ref-type="ref"} and remained the standard treatment until the early part of the 21st century. In experienced hands, this method has a cure rate of at least 95 per cent, with a morbidity rate of less than 3 per cent[5](#bjs577-bib-0005){ref-type="ref"}, and does not require any form of preoperative localization imaging.

It is widely recognized that in over 85 per cent of patients with PHPT the cause is a single overactive parathyroid adenoma, often identifiable through preoperative imaging, allowing selective removal[5](#bjs577-bib-0005){ref-type="ref"}. The two most common modalities of preoperative localization are sestamibi imaging and high‐resolution ultrasonography. A meta‐analysis[6](#bjs577-bib-0006){ref-type="ref"} examining the value of ultrasound imaging in PHPT found an overall pooled sensitivity of 76·1 per cent and a positive predictive value of 93·2 per cent, although operator and centre variation was acknowledged[7](#bjs577-bib-0007){ref-type="ref"}. With negative localization of a solitary adenoma, the likelihood of multiglandular disease is reported to be up to 30 per cent[8](#bjs577-bib-0008){ref-type="ref"} [9](#bjs577-bib-0009){ref-type="ref"}.

Surgical management of PHPT has evolved over the past 20 years. Rapid intraoperative parathyroid hormone (IOPTH) assay[10](#bjs577-bib-0010){ref-type="ref"}, sestamibi scintigraphy and radio‐guided parathyroidectomy[11](#bjs577-bib-0011){ref-type="ref"} have emerged, facilitating the development of 'targeted' parathyroidectomy techniques based on single‐gland excision via unilateral neck exploration. Various techniques have been described[12](#bjs577-bib-0012){ref-type="ref"}, [13](#bjs577-bib-0013){ref-type="ref"}, [14](#bjs577-bib-0014){ref-type="ref"}, [15](#bjs577-bib-0015){ref-type="ref"}, with a general consensus that parathyroidectomy is classified as 'minimally invasive' when performed with preoperative localization through an incision of less than 2·5--3 cm[5](#bjs577-bib-0005){ref-type="ref"} [12](#bjs577-bib-0012){ref-type="ref"}, [13](#bjs577-bib-0013){ref-type="ref"}.

Targeted minimally invasive parathyroidectomy (MIP) has been shown in large studies, systematic reviews and meta‐analysis to be highly effective with low complication rates compared with open bilateral neck exploration (BNE)[14](#bjs577-bib-0014){ref-type="ref"}, [15](#bjs577-bib-0015){ref-type="ref"}, [16](#bjs577-bib-0016){ref-type="ref"}. Advantages of MIP include shorter duration of surgery, lower rates of postoperative hypocalcaemia, less postoperative pain and a smaller scar[17](#bjs577-bib-0017){ref-type="ref"}. There are also potential financial advantages in performing MIP[18](#bjs577-bib-0018){ref-type="ref"} [19](#bjs577-bib-0019){ref-type="ref"}, with lower operative costs and more rapid hospital discharge.

The consensus statement published by the European Society of Endocrine Surgeons (ESES)[20](#bjs577-bib-0020){ref-type="ref"} described MIP as a safe and cost‐effective procedure for the treatment of selected patients with PHPT. In the UK, the National Institute for Health and Care Excellence (NICE) released guidelines for minimally invasive video‐assisted parathyroidectomy (MIVAP)[21](#bjs577-bib-0021){ref-type="ref"}, stating that 'current evidence on the efficacy and safety of MIVAP is adequate to support the use of this procedure'.

Misdiagnosis and the risk of undertreating multigland disease, leading to high recurrence rates, nevertheless remains a potential shortcoming of this approach. This systematic review aimed to examine long‐term (1 year or more) recurrence rates following targeted MIP in PHPT.

Methods {#bjs577-sec-0006}
=======

Acquisition of evidence {#bjs577-sec-0007}
-----------------------

The PRISMA protocol[22](#bjs577-bib-0022){ref-type="ref"} was followed to perform a comprehensive literature search using MEDLINE, Embase, CINAHL, the UK Clinical Trials Gateway and the US Trials Database between January 2004 and March 2017. The PICO framework[23](#bjs577-bib-0023){ref-type="ref"} was used and terms combined with Boolean operators (AND, OR) to refine the search further.

Two independent reviewers identified all studies that met the inclusion criteria for full review. References of the searched studies were evaluated for potential inclusion in the review. Where possible, contact was attempted with authors to verify data that were not clearly described or to confirm that specific data were not available from the study. The study included all articles published between January 2004 and March 2017 that reported MIP alone or comparison with BNE, involving at least 50 patients, where recurrence rates were documented and mean follow‐up was at least 1 year. Parathyroidectomy was considered minimally invasive if the authors documented incision of 3 cm or less, or if MIP was clearly stated. Only articles published in English were considered, and no age limits were set.

To analyse the best available data focusing on long‐term (follow‐up of at least 1 year) recurrence and cure rates, the inclusion criterion for centres performing MIP regularly (at least 50 patients per annum) was set. This was done to minimize skewing of data from 'low‐volume' centres and small case series.

Study quality and levels of evidence {#bjs577-sec-0008}
------------------------------------

The quality of studies and risk of bias were assessed by two reviewers. All studies included in the review were non‐randomized, and therefore the Methodological Index for Non‐Randomized Studies (MINORS) tool[24](#bjs577-bib-0024){ref-type="ref"} was used. This tool assessed non‐randomized studies on the following criteria: clearly stated aims, inclusion of consecutive patients, prospective data collection, appropriate endpoints, unbiased evaluation of endpoints, appropriate duration of follow‐up and loss to follow‐up no more than 5 per cent. For comparative studies, further criteria were assessed: whether the control group underwent a standard intervention, the use of contemporary groups, baseline equivalence of the groups, prospective calculation of the sample size and statistical analysis adapted to the study design.

To ascertain the level of evidence of the included studies, the Oxford Centre for Evidence‐based Medicine (OCEM)[25](#bjs577-bib-0025){ref-type="ref"} guidelines were employed.

Outcomes {#bjs577-sec-0009}
--------

The primary outcome was recurrence rate, defined as the rate of hypercalcaemia occurring after 6 months of normocalcaemia following parathyroidectomy.

Secondary outcomes were: cure rate (defined as normocalcaemia persisting for more than 6 months after surgery), type of MIP performed, use of IOPTH measurements and postoperative complication rate.

When analysing IOPTH use and non‐use during MIP, the studies were divided into those that included only patients who exhibited positive preoperative concordant imaging (PC cohort) and those that included a heterogeneous cohort (H cohort: 1--2 image‐positive or image‐negative patients).

Statistical analysis {#bjs577-sec-0010}
--------------------

GraphPad Prism^®^ version 7.0d (GraphPad Software, La Jolla, California, USA) was used for statistical analysis, and Microsoft Excel^®^ version 16.12 (Microsoft, Redmond, Washington, USA) for data handling. The statistical significance of categorical variables was determined with Fisher\'s exact test. *P* \< 0·050 was considered statistically significant.

Results {#bjs577-sec-0011}
=======

Study identification {#bjs577-sec-0012}
--------------------

The initial literature search yielded a total of 252 studies, of which 14[11](#bjs577-bib-0011){ref-type="ref"} [20](#bjs577-bib-0020){ref-type="ref"}, [26](#bjs577-bib-0026){ref-type="ref"}, [27](#bjs577-bib-0027){ref-type="ref"}, [28](#bjs577-bib-0028){ref-type="ref"}, [29](#bjs577-bib-0029){ref-type="ref"}, [30](#bjs577-bib-0030){ref-type="ref"}, [31](#bjs577-bib-0031){ref-type="ref"}, [32](#bjs577-bib-0032){ref-type="ref"}, [33](#bjs577-bib-0033){ref-type="ref"}, [34](#bjs577-bib-0034){ref-type="ref"}, [35](#bjs577-bib-0035){ref-type="ref"}, [36](#bjs577-bib-0036){ref-type="ref"}, [37](#bjs577-bib-0037){ref-type="ref"} met the inclusion criteria (*Fig*. [1](#bjs577-fig-0001){ref-type="fig"}). All studies were observational and included a total of 5282 patients who had targeted MIP for PHPT. There was a female preponderance of 3·4 : 1 and the overall mean age was 58·9 years (*Table* [1](#bjs577-tbl-0001){ref-type="table"}).

![PRISMA diagram for the study](BJS5-2-364-g001){#bjs577-fig-0001}

###### 

Summary of included studies

  Reference                                                    Review period    Study type     No. of patients   Sex ratio (M : F)      Age (years)[\*](#bjs577-note-0001){ref-type="fn"}      Mean recurrence rate (%)[\*](#bjs577-note-0001){ref-type="fn"}   Mean cure rate (%)[\*](#bjs577-note-0001){ref-type="fn"}   Follow‐up (months)[\*](#bjs577-note-0001){ref-type="fn"}
  ----------------------------------------------------------- --------------- --------------- ----------------- ------------------- --------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Chen *et al*.[26](#bjs577-bib-0026){ref-type="ref"}           1990--2004     Retrospective         188               n.d.                                   60(3)                                                         1·1                                                           99·0                                                        48
  Cohen *et al*.[27](#bjs577-bib-0027){ref-type="ref"}          1999--2004     Retrospective         139             32 : 107                            60(15) (16‐88)                                                     0·0                                                           98·6                                                  15(12) (3--38)
  Barczynski *et al*.[20](#bjs577-bib-0020){ref-type="ref"}     2000--2006      Prospective          115              18 : 97                              57·1(12·2)                                                       0·9                                                           98·3                                                  28(10) (6--42)
  Mihai *et al*.[32](#bjs577-bib-0032){ref-type="ref"}          2001--2006      Prospective          150             46 : 104                            60(16) (17--89)                                                    0·0                                                           99·3                                                  15(10) (3--48)
  Fouquet *et al*.[33](#bjs577-bib-0033){ref-type="ref"}        2001--2008      Prospective          200             35 : 165                             63·1 (13--87)                                                     0·5                                                           98·0                                                  13(13) (6--72)
  Venkat *et al*.[34](#bjs577-bib-0034){ref-type="ref"}         2004--2009      Prospective          200             51 : 149                          58·7(11·9) (13--88)                                                  2·5                                                           97·0                                                  37(19) (6--72)
  Barczyński *et al*.[28](#bjs577-bib-0028){ref-type="ref"}     2003--2012     Retrospective         455             57 : 398                          54·7(15·6) (18--82)                                                  2·3                                                           99·6                                                 43(16) (12--112)
  Chow *et al*.[29](#bjs577-bib-0029){ref-type="ref"}           2002--2012     Retrospective         105              29 : 76                              61·5(14·6)                                                       0·0                                                           n.d.                                                       56·9
  Norlén *et al*.[31](#bjs577-bib-0031){ref-type="ref"}         1990--2013     Retrospective        2531            593 : 1938                             61·8(13·9)                                                       1·8                                                           95·5                                 78 (1--24)[†](#bjs577-note-0002){ref-type="fn"}
  Day *et al*.[35](#bjs577-bib-0035){ref-type="ref"}            2003--2013      Prospective          556             147 : 409                             61·1(13·4)                                                       2·0                                                           97·3                                                   44 (1--145)
  Yang *et al*.[30](#bjs577-bib-0030){ref-type="ref"}           2008--2012     Retrospective         115              37 : 78           46 (28--57)[†](#bjs577-note-0002){ref-type="fn"}                                    0·9                                                           99·1                                                        24
  Nijhuis *et al*.[37](#bjs577-bib-0037){ref-type="ref"}        2000--2013         n.d.              114               n.d.                                   n.d.                                                          3·5                                                           96·5                                     34[†](#bjs577-note-0002){ref-type="fn"}
  Thier *et al*.[36](#bjs577-bib-0036){ref-type="ref"}          1989--2010      Prospective          292             58 : 234        66[†](#bjs577-note-0002){ref-type="fn"} (i.q.r. 57--75)                                0·3                                                       1 year: 98·5                             60 (1--180)[†](#bjs577-note-0002){ref-type="fn"}
  5 years: 99·4                                                                                                                                                                                                                                                                                                           
  10 and 15 years: 100                                                                                                                                                                                                                                                                                                    
  Kim *et al*.[11](#bjs577-bib-0011){ref-type="ref"}            2000--2012     Retrospective         122              28 : 94                               50·8(13)                                                        0·0                                                           99·2                                                    45·5(42·2)

Values are mean(s.d.) (range) unless indicated otherwise;

values are median (range) unless indicated otherwise. n.d., Not documented.

Quality of studies and levels of evidence {#bjs577-sec-0013}
-----------------------------------------

Of the 14 studies, seven were retrospective[11](#bjs577-bib-0011){ref-type="ref"} [26](#bjs577-bib-0026){ref-type="ref"}, [27](#bjs577-bib-0027){ref-type="ref"}, [28](#bjs577-bib-0028){ref-type="ref"}, [29](#bjs577-bib-0029){ref-type="ref"}, [30](#bjs577-bib-0030){ref-type="ref"}, [31](#bjs577-bib-0031){ref-type="ref"}, six involved collection of prospectively identified items[20](#bjs577-bib-0020){ref-type="ref"} [32](#bjs577-bib-0032){ref-type="ref"}, [33](#bjs577-bib-0033){ref-type="ref"}, [34](#bjs577-bib-0034){ref-type="ref"}, [35](#bjs577-bib-0035){ref-type="ref"}, [36](#bjs577-bib-0036){ref-type="ref"} and one[37](#bjs577-bib-0037){ref-type="ref"} did not clarify the type of study. The median MINORS score was 10 of 16 (mean 9·8, range 6--14) for all studies, and the median of the four comparative studies[11](#bjs577-bib-0011){ref-type="ref"} [20](#bjs577-bib-0020){ref-type="ref"}, [26](#bjs577-bib-0026){ref-type="ref"} [28](#bjs577-bib-0028){ref-type="ref"} was 15 of 24 (mean 14·25, range 10--17).

According to the OCEM criteria, all of the included studies were classified as individual cohort studies and were therefore classified as having level 2b evidence.

Outcomes {#bjs577-sec-0014}
--------

The overall mean recurrence rate for the 5282 patients was 1·6 (range 0--3·5) per cent, and the overall cure rate 96·9 (95·5--100) per cent. The overall mean duration of follow‐up for the studies included was 33·5 (1--145) months (*Table* [1](#bjs577-tbl-0001){ref-type="table"}).

All studies defined cure as normalization of serum calcium levels, and all recorded serum calcium levels at each follow‐up appointment. All but three studies[26](#bjs577-bib-0026){ref-type="ref"} [31](#bjs577-bib-0031){ref-type="ref"}, [37](#bjs577-bib-0037){ref-type="ref"} also measured postoperative serum PTH levels routinely.

All studies used the widely accepted definition of 'disease recurrence' as hypercalcaemia after 6 months of proven normocalcaemia following initial surgery.

The most common type of surgery performed was the open MIP technique[26](#bjs577-bib-0026){ref-type="ref"} [27](#bjs577-bib-0027){ref-type="ref"}, [29](#bjs577-bib-0029){ref-type="ref"}, [30](#bjs577-bib-0030){ref-type="ref"}, [31](#bjs577-bib-0031){ref-type="ref"}, [32](#bjs577-bib-0032){ref-type="ref"} [34](#bjs577-bib-0034){ref-type="ref"}, [35](#bjs577-bib-0035){ref-type="ref"}, [36](#bjs577-bib-0036){ref-type="ref"}, [37](#bjs577-bib-0037){ref-type="ref"}, but other approaches included MIVAP[20](#bjs577-bib-0020){ref-type="ref"} [28](#bjs577-bib-0028){ref-type="ref"}, minimally invasive radio‐guided parathyroidectomy[11](#bjs577-bib-0011){ref-type="ref"} and a totally endoscopic MIP technique[33](#bjs577-bib-0033){ref-type="ref"}. When reported, studies had incision lengths of less than 3 cm, whereas studies that did not report on incision length stated that their procedure was 'minimally invasive' or a 'focused/lateral exploration'.

Four studies[11](#bjs577-bib-0011){ref-type="ref"} [29](#bjs577-bib-0029){ref-type="ref"}, [31](#bjs577-bib-0031){ref-type="ref"} [32](#bjs577-bib-0032){ref-type="ref"} with a total of 2908 patients performed targeted MIP without IOPTH measurements, and nine studies[20](#bjs577-bib-0020){ref-type="ref"} [26](#bjs577-bib-0026){ref-type="ref"}, [27](#bjs577-bib-0027){ref-type="ref"}, [28](#bjs577-bib-0028){ref-type="ref"} [30](#bjs577-bib-0030){ref-type="ref"}, [33](#bjs577-bib-0033){ref-type="ref"}, [34](#bjs577-bib-0034){ref-type="ref"}, [35](#bjs577-bib-0035){ref-type="ref"}, [36](#bjs577-bib-0036){ref-type="ref"} carried out targeted MIP with IOPTH measurements in 2072 of the patients. One study[37](#bjs577-bib-0037){ref-type="ref"} made no reference to the use of this test, so was not included in the analysis. Five studies[28](#bjs577-bib-0028){ref-type="ref"}, [29](#bjs577-bib-0029){ref-type="ref"}, [30](#bjs577-bib-0030){ref-type="ref"}, [31](#bjs577-bib-0031){ref-type="ref"}, [32](#bjs577-bib-0032){ref-type="ref"} included only patients with positive, concordant preoperative localization studies on at least two different imaging modalities, seven[11](#bjs577-bib-0011){ref-type="ref"} [20](#bjs577-bib-0020){ref-type="ref"}, [27](#bjs577-bib-0027){ref-type="ref"} [33](#bjs577-bib-0033){ref-type="ref"}, [34](#bjs577-bib-0034){ref-type="ref"}, [35](#bjs577-bib-0035){ref-type="ref"}, [36](#bjs577-bib-0036){ref-type="ref"} included patients regardless of imaging findings, and two[26](#bjs577-bib-0026){ref-type="ref"} [37](#bjs577-bib-0037){ref-type="ref"} did not report on imaging findings.

When IOPTH measurement was not done during MIP, overall mean cure rates were higher (99·3 per cent *versus* 98·1 per cent when IOPTH measurement was done; *P* \< 0·001) and recurrence rates were lower (0·2 *versus* 1·5 per cent respectively; *P* \< 0·001) (*Table* [2](#bjs577-tbl-0002){ref-type="table"}).

###### 

Recurrence and cure rates according to patient cohort and intraoperative parathyroid hormone measurement

                                            IOPTH measurement   No IOPTH measurement   Overall                            
  ---------------------------------------- ------------------- ---------------------- --------- ----- ------ ------ ----- ------
  Preoperative concordant imaging cohort           2·0                  99·5             570     0·2   99·3   2786   0·5   99·3
  Heterogeneous cohort                             1·3                  95·6            1502     0·0   99·2   122    1·7   97·7
  Overall                                          1·5                  98·1            2072     0·2   99·3   2908        

IOPTH, intraoperative parathyroid hormone.

An overall complication rate of 4·4 per cent in 4010 patients was reported in nine studies[20](#bjs577-bib-0020){ref-type="ref"} [27](#bjs577-bib-0027){ref-type="ref"}, [28](#bjs577-bib-0028){ref-type="ref"}, [29](#bjs577-bib-0029){ref-type="ref"}, [30](#bjs577-bib-0030){ref-type="ref"}, [31](#bjs577-bib-0031){ref-type="ref"}, [32](#bjs577-bib-0032){ref-type="ref"}, [33](#bjs577-bib-0033){ref-type="ref"}, [34](#bjs577-bib-0034){ref-type="ref"}, whereas five[11](#bjs577-bib-0011){ref-type="ref"} [26](#bjs577-bib-0026){ref-type="ref"}, [35](#bjs577-bib-0035){ref-type="ref"}, [36](#bjs577-bib-0036){ref-type="ref"}, [37](#bjs577-bib-0037){ref-type="ref"} did not report complication rates. Transient and permanent postoperative hypocalcaemia rates were 1·6 and 0·05 per cent respectively. Temporary recurrent laryngeal nerve (RLN) palsy occurred in 1·1 per cent and permanent RLN palsy in 0·3 per cent of the 4010 patients. Complications are summarized in *Table* [3](#bjs577-tbl-0003){ref-type="table"}.

###### 

Complications

                                                                                                                                           No. of complications (*n* = 176)
  --------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Temporary RLN palsy seen on laryngoscopy                                                                                                            35 (19·9)
  Transient hypocalcaemia defined as \< 2 mmol/l                                                                                                      23 (13·1)
  Transient hypocalcaemia defined as ≤ 1·95 mmol/l                                                                                                    23 (13·1)
  Hypocalcaemia (NOS)                                                                                                                                 22 (12·5)
  Temporary hypoparathyroidism defined as hypocalcaemia (NOS) requiring calcium or vitamin D supplementation, resolving within 6 months                17 (9·7)
  Other complication (NOS)                                                                                                                             13 (7·4)
  Permanent RLN palsy seen on laryngoscopy                                                                                                             11 (6·3)
  Wound haematoma requiring return to theatre for evacuation                                                                                           8 (4·5)
  Temporary RLN palsy (laryngoscopy use not documented)                                                                                                7 (4·0)
  Wound infection                                                                                                                                      4 (2·3)
  Myocardial infarction                                                                                                                                2 (1·1)
  Temporary RLN palsy (selective use of laryngoscopy)                                                                                                  2 (1·1)
  Permanent hypoparathyroidism defined as hypocalcaemia (NOS) requiring calcium or vitamin D supplementation, persisting after 6 months                2 (1·1)
  Mild neck swelling, managed conservatively                                                                                                           1 (0·6)
  Transient hypercalcaemia returning to normal                                                                                                         1 (0·6)
  Wound haematoma, managed conservatively                                                                                                              1 (0·6)
  Permanent RLN palsy (laryngoscopy use not documented)                                                                                                1 (0·6)
  Cerebrovascular accident                                                                                                                             1 (0·6)
  Permanent RLN palsy (selective use of laryngoscopy)                                                                                                  1 (0·6)
  30‐day mortality not related to surgery                                                                                                              1 (0·6)

Values in parentheses are percentages. RLN, recurrent laryngeal nerve; NOS, not otherwise specified.

There were significant differences in how complications were defined and reported. In terms of RLN palsy, four studies[20](#bjs577-bib-0020){ref-type="ref"} [28](#bjs577-bib-0028){ref-type="ref"}, [31](#bjs577-bib-0031){ref-type="ref"} [40](#bjs577-bib-0040){ref-type="ref"} routinely used laryngoscopy after surgery, one study[29](#bjs577-bib-0029){ref-type="ref"} used laryngoscopy in patients with postoperative dysphonia, and another study[30](#bjs577-bib-0030){ref-type="ref"} explicitly stated that laryngoscopy was not used. The remaining publications did not comment on postoperative laryngoscopy. The definition of hypocalcaemia also varied, from a serum calcium level lower than 2 mmol/l[28](#bjs577-bib-0028){ref-type="ref"} to 1·95 mmol/l or less[30](#bjs577-bib-0030){ref-type="ref"}, whereas other studies did not define cut‐off levels.

Discussion {#bjs577-sec-0015}
==========

This systematic review has indicated that, despite variations in technique, targeted MIP was associated with low long‐term (at least 1 year) recurrence rates of only about 1·5 per cent.

Overall recurrence rates were lowest and cure rates highest in studies that included patients where there was positive, concordant preoperative localization. Interestingly, the analysis suggested that recurrence and cure rates were better when IOPTH measurements were not used. As indicated in *Table* [2](#bjs577-tbl-0002){ref-type="table"}, this appeared to reflect use of MIP without routine IOPTH measurement in patients with concordant imaging. IOPTH measurement seemed to be used more frequently in non‐concordant or image‐negative patients.

Two reports[38](#bjs577-bib-0038){ref-type="ref"} [39](#bjs577-bib-0039){ref-type="ref"} relating to MIP were not included in this systematic review as they did not fulfil the inclusion criteria (mean duration of follow‐up not documented). These studies reported a median follow‐up of 9 (range 0--116) months. The first study[38](#bjs577-bib-0038){ref-type="ref"} investigated whether MIP was associated with a higher recurrence rate than BNE, and the second[39](#bjs577-bib-0039){ref-type="ref"} considered variables that might predict recurrence in parathyroidectomy for PHPT. In both studies, Kaplan--Meier curves were constructed to determine disease‐free estimates for MIP and BNE. No statistically significant differences were found between MIP and open parathyroidectomy in either study (*P* = 0·55 and *P* = 0·59 respectively).

A meta‐analysis[14](#bjs577-bib-0014){ref-type="ref"} of studies comparing focused parathyroidectomy with conventional BNE found that recurrence (odds ratio (OR) 1·08, 95 per cent c.i. 0·59 to 2·00; *P* = 0·80) and failure (OR 0·88, 0·58 to 1·34; *P* = 0·56) rates were comparable. Complication rates were significantly lower in the focused parathyroidectomy arm (OR 0·35, 0·15 to 0·84; *P* = 0·02), predominantly related to a lower risk of transient hypocalcaemia (OR 0·36, 0·14 to 0·90; *P* = 0·03). The present review is consistent with these findings, with a 1·6 per cent temporary and 0·05 per cent permanent postoperative hypocalcaemia rate after MIP.

This review also demonstrated the overall complication rate to be low (4·4 per cent in 4010 patients), and similar to values reported by previous large studies[15](#bjs577-bib-0015){ref-type="ref"} [40](#bjs577-bib-0040){ref-type="ref"} involving BNE, together with similar rates of permanent and temporary recurrent laryngeal nerve palsy (0·3 and 1·1 per cent respectively). The lack of postoperative laryngoscopy in the present review and in other studies, however, may mean that the true rate of recurrent nerve palsy is underestimated. Similar consideration applies to rates of postoperative hypocalcaemia, owing to the different cut‐off levels.

This systematic review analysed 14 level 2b studies with a median MINORS score of 10 (mean 9·8), indicating evidence of fair quality. However, its main limitation was the lack of uniformity in the presentation and reporting of data by the individual studies. This is a widely recognized and inherent problem of collating data from observational studies.

Despite these shortcomings, targeted MIP in the surgical management of patients with a presumed single overactive parathyroid adenoma is a safe technique that provides long‐term cure. The review also suggests that MIP is effective without intraoperative hormone estimations in patients with preoperative concordant imaging.

Disclosure {#bjs577-sec-0016}
==========

The authors declare no conflict of interest.
